Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil class action settlement

Executive Summary

A Minnesota District Court judge on Sept. 28 approved a class action settlement under which GlaxoSmithKline will pay $40 million to reimburse third party payers for costs of Paxil (paroxetine) prescribed to persons under the age of 18. Plaintiffs claimed GSK promoted Paxil for children when clinical trials showed the antidepressant had a greater risk of suicide risk than placebo. Last year GSK settled a class action involving parents who sought reimbursement for Paxil prescriptions

You may also be interested in...



BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A

Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.

BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

Lawmakers Press CMS To Enact MCIT Breakthrough Device Coverage Rule

The Medicare rule, which was delayed by 60 days under a broader regulatory freeze, is seen as critical to the reimbursement of innovative devices.

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel